Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight
Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight
DelveInsight's ‘Systemic Lupus Erythematosus Pipeline Insight 2021' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain.
Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report:
- DelveInsight's Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies.
- Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.
- Essential Systemic Lupus Erythematosus pipeline therapies such as TJ202, PF-06835375, Itolizumab, KPG 818, ICP-022, BOS161721, NKTR-358, ABBV-599, Deucravacitinib, SAR441344, BIIB059, Baricitinib, Obinutuzumab, LY3471851, TX200-TR101, Forigerimod, CS 12192, Zilucoplan, Ivarmacitinib, Research program: therapeutics, Solute carrier family 15 member 4 inhibitor and others are under development in different phases of clinical trials.
- In September 2019, Eli Lilly and Company initiated a Phase III, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus. The trial is currently active with 1100 participants and is anticipated to get completed by May 2025.
- BenevolentAI has entered into a 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure.
- Provention Bio has commenced a Phase IIa clinical trial of its investigational humanized bispecific DART molecule, PRV-3279, to treat patients with moderate-to-severe Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease.
- On February 1, 2022, Biogen Inc. announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies' long-standing collaboration on antibodies targeting CD20. Mosunetuzumab is currently in Phase Ib stage of development in people with SLE.
- A Phase IIb study of rozibafusp alfa, a multispecific antibody-peptide fusion that simultaneously blocks inducible T-cell costimulatory ligand (ICOSL) and B-cell activating factor (BAFF) activity, is being investigated to treat patients with Systemic Lupus Erythematosus.
Request a sample and discover more about the report offerings @ Systemic Lupus Erythematosus Emerging Therapies
The Systemic Lupus Erythematosus pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Systemic Lupus Erythematosus products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Systemic Lupus Erythematosus pipeline landscape.
Systemic Lupus Erythematosus Overview
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The pathogenesis of Systemic Lupus Erythematosus is complex, and the understanding of SLE pathogenesis is constantly evolving. A break in the tolerance in genetically susceptible individuals, on exposure to environmental factors, leads to the activation of autoimmunity.
Find out more about the disease and recent developments @ Systemic Lupus Erythematosus Pipeline Assessment
Systemic Lupus Erythematosus Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| TJ202 | I-Mab Biopharma | Phase I | Antibody-dependent cell cytotoxicity; Phagocyte stimulants | Intravenous |
| PF-06835375 | Pfizer | Phase I | CXCR5 receptor antagonists; Immunomodulators | Intravenous/ Subcutaneous |
| Itolizumab | Equillium/Biocon Limited | Phase I | CD6 antigen inhibitors | Subcutaneous |
| KPG 818 | Kangpu Biopharmaceuticals | Phase I/II | CRBN protein modulators; Ubiquitin protein ligase complex modulators | Oral |
| ICP-022 | InnoCare Pharma | Phase I/II | Agammaglobulinaemia tyrosine kinase inhibitors | Oral |
| BOS161721 | Boston Pharmaceuticals | Phase I/II | Interleukin 21 inhibitors | Subcutaneous |
| NKTR-358 | Nektar Therapeutics | Phase II | NA | Subcutaneous |
| ABBV-599 | AbbVie | Phase II | Agammaglobulinaemia tyrosine kinase inhibitors; Janus kinase 1 inhibitors | Oral |
| Deucravacitinib | Bristol Myers Squibb | Phase II | TYK2 kinase inhibitors | Intravenous |
| SAR441344 | Sanofi | Phase II | CD40 ligand inhibitors | Intravenous/ Subcutaneous |
| BIIB059 | Biogen | Phase III | CLEC4C protein inhibitors | Subcutaneous |
| Baricitinib | Eli Lilly and Company | Phase III | Janus kinase 1 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors | Oral |
| Obinutuzumab | Hoffman-La-Roche | Phase III | Antibody-dependent cell cytotoxicity; Cell death stimulants | Intravenous |
| Forigerimod | ImmuPharma | Phase III | Immunomodulators | Subcutaneous |
Learn more about the novel and emerging Systemic Lupus Erythematosus pipeline therapies @ Systemic Lupus Erythematosus Pipeline Analysis
Systemic Lupus Erythematosus Therapeutics Assessment
The Systemic Lupus Erythematosus Pipeline report proffers an integral view of the Systemic Lupus Erythematosus emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Systemic Lupus Erythematosus Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Systemic Lupus Erythematosus Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Systemic Lupus Erythematosus Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
- Therapeutics Assessment By Systemic Lupus Erythematosus Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
- Therapeutics Assessment By Systemic Lupus Erythematosus Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
- Therapeutics Assessment By Systemic Lupus Erythematosus Therapies Mechanism of Action: TYK2 kinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Antibody-dependent cell cytotoxicity, TYK2 kinase inhibitors, CLEC4C protein inhibitors, CD40 ligand inhibitors, Interleukin 21 inhibitors, CRBN protein modulators, CD6 antigen inhibitors, CXCR5 receptor antagonists
- Key Systemic Lupus Erythematosus Companies: AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics
- Key Systemic Lupus Erythematosus Pipeline Therapies: TJ202, PF-06835375, Itolizumab, KPG 818, ICP-022, BOS161721, NKTR-358, ABBV-599, Deucravacitinib, SAR441344, BIIB059, Baricitinib, Obinutuzumab, LY3471851, TX200-TR101, Forigerimod
Dive deep into rich insights for emerging therapies and assessment, visit @ Systemic Lupus Erythematosus Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Systemic Lupus Erythematosus: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Late Stage Products (Phase III) |
| 5.1 | Obinutuzumab: Hoffman-La-Roche |
| 6 | Late Stage Products (Phase III) |
| 6.1 | Baricitinib: Eli Lilly and Company |
| 7 | Mid Stage Products (Phase II) |
| 7.1 | ABBV-599: AbbVie |
| 8 | Mid Stage Products (Phase II) |
| 8.1 | SAR441344: Sanofi |
| 9 | Early Stage Products (Phase I/II) |
| 9.1 | BOS161721: Boston Pharmaceuticals |
| 10 | Early Stage Products (Phase I/II) |
| 10.1 | ICP-022: InnoCare Pharma |
| 11 | Therapeutic Assessment |
| 12 | Inactive Products |
| 13 | Collaborations Assessment- Licensing / Partnering / Funding |
| 14 | Systemic Lupus Erythematosus- Unmet Needs |
| 15 | Systemic Lupus Erythematosus- Market Drivers and Barriers |
| 16 | Appendix |
| 17 | About DelveInsight |
For further information on the Systemic Lupus Erythematosus current pipeline therapeutics, reach out @ Systemic Lupus Erythematosus Ongoing Clinical Trials
Related Reports
Cutaneous Lupus Erythematosus Market
DelveInsight's "Cutaneous Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, and others.
DelveInsight's ‘Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others
Intratumoral Cancer Therapies Market
DelveInsight's ‘Intratumoral Cancer Therapies - Market Insights, Epidemiology and Market Forecast—2030' report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Takara Bio, NanOlogy, Istari Oncology, Moderna Therapeutics, Intensity Therapeutics, and several others.
DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like Bayer Health Care, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.
DelveInsight's, "CAR-T – Pipeline Insights, 2021," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd. and others.
Acute Myeloid Leukemia Pipeline
DelveInsight's, "Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen, Kartos Therapeutics, Plexxikon, Shijiazhuang Yiling Pharmaceutical, JW Pharmaceutical, Hanmi Pharmaceutical, GEMoaB Monoclonals, and several others.
Interested to know more about the breakthrough happenings? Take a look at the posts below
Systemic Lupus Erythematosus Market: How the Leading Companies are Countering the Rising Prevalence?
Aurinia's Lupkynis for Lupus
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
